All In Biotech

Drug Trial Radar · NCT06332014

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

102

Actual

Start

Aug 6, 2024

Primary completion

Jan 23, 2027

Study completion Jan 23, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.

Conditions

  • Osteoporosis

Interventions

  • ProliaDrug

    Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12Time frame: Baseline and Month 12

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth Peoples Hospital

    Shanghai, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Jishuitan Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Sun Yat-sen Memorial Hospital Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China

  • The Fourth Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Huaian First Peoples Hospital

    Huaian, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Peoples Hospital of Kunshan

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Jiangxi Provincial Peoples Hospital

    Nanchang, Jiangxi, China

  • Pingxiang Peoples Hospital

    Pingxiang, Jiangxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.